Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Clinical trial NCT04734990 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04734990
Sponsor: M.D. Anderson Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Chronic Myelomonocytic Leukemia-0 Chronic Myelomonocytic Leukemia-1 Chronic Myelomonocytic Leukemia-2 Myelodysplastic Syndrome Recurrent Chronic Myelomonocytic Leukemia Recurrent Myelodysplastic Syndrome

Start date: 2021-07-07
Primary completion: 2027-09-11
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.